Neuromyelitis Optica Treatment Analysis of 36 Patients

dc.contributor.authorBichuetti, Denis Bernardi [UNIFESP]
dc.contributor.authorLobato de Oliveira, Enedina Maria [UNIFESP]
dc.contributor.authorOliveira, Daniel May [UNIFESP]
dc.contributor.authorSouza, Nilton Amorin de [UNIFESP]
dc.contributor.authorGabbai, Alberto Alain [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2018-06-15T13:56:00Z
dc.date.available2018-06-15T13:56:00Z
dc.date.issued2010-09-01
dc.description.abstractObjective: To analyze treatment response in Brazilian patients with neuromyelitis optica.Design: Retrospective review.Setting: Neuroimmunology Clinic of the Federal University of Sao Paulo, Sao Paulo, Brazil.Patients: Thirty-six patients with relapsing-remitting optic-spinal disease; long, extending spinal cord lesions; and brain magnetic resonance images not meeting Barkhof criteria for multiple sclerosis, thus fulfilling the 1999 and 2006 criteria for neuromyelitis optica. Patients were followed up from 1994 to 2007.Main Outcome Measures: Relapses and accumulation of disability.Results: Mean follow-up time was 47.2 months and mean age at onset was 32.3 years. Sixty-four treatments were implemented in 36 patients, which included interferon beta, methotrexate, cyclophosphamide, prednisone, and azathioprine solely or plus prednisone. Patients who were treated with azathioprine or azathioprine with prednisone had a reduction in the occurrence of relapses and Expanded Disability Severity Scale score stabilization, as opposed to patients who received other treatments. Of the 4 patients who died, only 1 had received azathioprine treatment.Conclusion: Azathioprine as monotherapy or with prednisone seems to have reduced the relapse frequency and halted disability progression in the majority of patients treated, with minor and manageable adverse effects.en
dc.description.affiliationUniv Fed Sao Paulo, Dept Neurol & Neurocirurgia, BR-04039900 Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Dept Neurol & Neurocirurgia, BR-04039900 Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipBayer Schering
dc.description.sponsorshipBiogen Idec
dc.description.sponsorshipMerck Serono
dc.description.sponsorshipTeva Pharmaceuticals
dc.format.extent1131-1136
dc.identifierhttp://dx.doi.org/10.1001/archneurol.2010.203
dc.identifier.citationArchives Of Neurology. Chicago: Amer Medical Assoc, v. 67, n. 9, p. 1131-1136, 2010.
dc.identifier.doi10.1001/archneurol.2010.203
dc.identifier.issn0003-9942
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/42648
dc.identifier.wosWOS:000282102800014
dc.language.isoeng
dc.publisherAmer Medical Assoc
dc.relation.ispartofArchives Of Neurology
dc.rightsAcesso aberto
dc.titleNeuromyelitis Optica Treatment Analysis of 36 Patientsen
dc.typeArtigo
Arquivos
Coleções